Categories
Blog

Foreign Site Reference Number | FSRN Fruitful Interim Measures

Foreign Site Reference NumberWho needs a Foreign Site Reference Number (FSRN)?

For Natural Health Products (NHPs) manufactured, packaged, and/or labeled by sites located outside of Canada, Canadian importers are required to provide evidence that these sites will be at par with Canadian Good Manufacturing Practices (GMP) under Part 3 of the Natural Health Products Regulations (NHPR).

This can be demonstrated using pre-cleared pieces of evidence or other acceptable evidence by the Site Licensing Guidance document. Foreign sites can be added to the site license application of Canadian importers by providing GMP evidence from the foreign site. This evidence is intended to demonstrate that manufacturing, packaging, and/or labeling operations carried out at foreign sites are in accordance with Part 3 of the NHPR.

FSRN thus helps in eliminating the need for a foreign site to provide the same GMP evidence multiple times for each importer’s Site License. It is important to note that a Foreign Site Reference Number is not a site license and hence cannot be regarded as authorization for the direct export of NHPs to Canada.

In a recently issued 4-page bulletin, the Natural and Non-prescription Health Products Directorate (NNHPD) has advised stakeholders regarding the interim measures on new Foreign Site Reference Number applications and renewal/modification of existing FSRNs. This bulletin also sheds light on interim measures for the validity of the Foreign Site Reference Number. If your FSRN meets certain criteria, you may be eligible for a longer validity period (extension).

  1. New Foreign Site Reference Number Applications – These applications will be reviewed upon annexation submission. Application for FSRN will be refused if not linked to a Canadian Importer. This measure is effective until further notice. Approval in the form of a Notice of Acceptance (NOA) will be issued if these conditions are met and the site is compliant. Previously FSRN submissions were reviewed and approved as their own application. Now the Foreign site must be linked to a Canadian importer upfront. Previously lower priority was placed on Foreign Site Reference Number applications that did not link to an importer’s site license. Now there is no mention of priority.

Need a licensed importer for your natural health products?

            2. Foreign Site Reference Number Renewal Application – FSRN will be extended until further notice if the site has been inspected by a qualified authority in the last 5 years (e.g., FDA) and there have been no risk issues flagged by a recognized authority (e.g., FDA). FSRNs that were issued based on QAR or SNC from 2020-to 2023 will also be extended.

FSRN holders are required to notify the NNHPD if there are any changes to the site’s GMP that may cause a risk to health, such as a regulatory action.

Each FSRN will be re-reviewed when it is included/linked to a new importer’s submission to ensure there is no risk associated with the site. Previously FSRN sites having expiry dates were required to be renewed prior to that date.

3. Modifications to an existing Foreign Site Reference Number – When submitting changes to FSRN, the information will only be evaluated (in parallel) when the change is also submitted/ initiated by an importer or site license holder. Previously FSRNs were updated and reviewed without being triggered by a site license amendment.

As per these interim measures, the Foreign Site Reference Number holder is responsible for the following:

  • Providing FSRNA (authorization) form to each Canadian importer
  • Providing required records to site license holders in a timely manner
  • Providing required records at the time of site license submission, annexation, and renewal

These requirements are the same as earlier and there are no changes to previous requirements.

According to the interim measures, the Site License holder’s (Canadian Importer) responsibilities include:

  • Finished product testing and stability studies are conducted in accordance with Part 3 of NHPR and the relevant records are held by the importer
  • Ensuring that records are available from Foreign Sites in one of the official languages (i.e., English and/or French)
  • Ensuring that relevant records for production and quality such as Master production documents, recalls, complaints, etc. are retained and readily available

Planning is a critical component of any site licensing activities; hence it is crucial to keep abreast with the impacts of these changes to the plans for your products, sites, and their operational activities. Our experts at Quality Smart Solutions can offer support to your needs for foods, cosmetics, Natural Health Products, NHP Site LicensingOTC drugs, and medical devices for North America. 

References:

https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/legislation-guidelines/guidance-documents/good-manufacturing-practices.html

https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/legislation-guidelines/guidance-documents/site-licensing-guidance-document.html

https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/applications-submissions/site-licensing/forms/foreign-site-reference-number-authorization-form-site-licensing.html

Categories
News

Update on Performance Standards and System Updates for NHP Applications

COVID had significantly impacted the processing of NHP product license applications with delays in the processing of all classes of applications with respect to the established service standards outlined in the Natural Health Products Management of Applications Policy. Similar delays were observed for NHP site license submissions. After the worst of the COVID-19 pandemic had passed, the NNHPD ramped up the review process to clear the backlog of non-priority product, site, and post-license submissions. As a result, regular updates are being provided by the NNHPD via the Performance standards for NHP applications Stakeholder Meetings, with the most recent one being March 23, 2022.

For non-COVID submissions (April 2021 to February 2022) 9,297 NHPs were licensed which includes 53% Class I; 13% Class II; 34% Class III applications. 718 sites were licensed/renewed. As per the recent performance standards for Class I applications, 93.4 % of new applications and amendments were processed within the service standard (60 calendar days) while for class II (service standard – 90 calendar days) and class III applications (service standard – 210 calendar days), these numbers were 87.8% and 59.6% respectively.

Post-licensing submissions are subdivided into two categories: amendments and notifications. Amendments are defined changes to an NHP that may have an impact on the safety, efficacy, and/or quality of the product. On the other hand, notifications are defined as changes to an NHP that do not significantly impact the product’s safety, efficacy, and/or quality.  Product license amendments follow the service standards as applicable for the relevant class of application while notifications have no established service standards. As per the recent data released on performance standards, 98% and 71% of notifications received in 2021 and 2022 respectively were processed.

Within the past year, the NNHPD has managed to achieve 50% year-to-date performance for new applications and amendments for non-COVID stream I Site Licence Applications while for stream II the numbers were 81% year-to-date performance for new applications and amendments. 318 site licence renewals were completed this fiscal year

System updates for Product Licence Applications

The web-based Product Licence Application (web PLA) form is an integral component of any natural health product license submission package. The basis of developing this web-based platform is to allow web PLA form searches and ease of populating data from the Natural Health Products Ingredients Database (NHPID). Earlier version 3 and version 4 were available. Web PLA version 4 allowed in-form compendial (NNHPD monograph) (class I) validation as opposed to web PLA version 3.

Several system improvements have been implemented to support priorities for Product Licence Applications. New web PLA version 4 was released on April 9, 2022. 

Looking for assistance with NHP licensing?

With the release of this latest version of web-based PLA, it was announced that web version 3 will be discontinued for new product license applications. Access to NNHPD web PLA previously finalized using version 3 will still be available for responding to IRNs. Also, these version 3 applications will be available for viewing using any browser and responding to IRNs until the end of November 2022.

It was also announced that moving forward, web PLA version 4 will support the selection and population of both validated and non-validated monographs. The validation supported monograph table was removed from the system. Following changes/updates were proposed for the new NNHPD web PLA version 4.

  • As per the Natural Health Products Management of Applications Policy, class I applications are required to comply with all the parameters of an individual monograph. The number of NNHPD monographs that can be referenced is subject to the maximum of one for class I applications while this number can be two or more NNHPD monographs for class II applications. Earlier web PLA version 3 was recommended for all classes of applications based on non-validation supported NNHPD monographs, but the recent version can be used for all monographs including the ones that are not validation-supported. These monographs will be included in the picklist and marked as “(validation unavailable)”. Such applications will be finalized without validation with the status being displayed as “Not validated”.
  • Aside from the above changes, several other changes have been made to the web PLA to make it more user-friendly and sensical. For example – the option to choose a dual-route of administration to support aromatherapy submissions, excluding pregnant and breastfeeding risk statements for products intended for male sub-population only, etc.

System updates for Web Site Licence Application (web SLA)

Version 3.0 of the web SLA was released in April 2022. Several updates have been made to make this new version more intuitive and detailed. Some of these changes include the addition of options to include qualification of the Quality Assurance Person, new validation features, the addition of an NPN lookup in the Product Information module, etc.

The ever-present changes with these updates in system and performance standards make it increasingly challenging to keep up with the most up-to-date regulatory information.  Planning is a critical component of any product launch or site licensing activities; hence it is crucial to be keep abreast with the impacts of these changes to the plans for your products, sites, and their operational activities. 

Subscribe to global regulatory updates

We use cookies to display personalized content, analyze site traffic, provide recommendations, and ensure you have a great browsing experience. By continuing to use our site, you consent to our use of cookies. Privacy Policy.